期刊文献+

阿托伐他汀治疗冠状动脉慢血流患者29例疗效分析 被引量:6

下载PDF
导出
摘要 目的:探讨阿托伐他汀治疗冠状动脉慢血流(SCF)患者的疗效及机制。方法:入选通过TIMI帧计数(TFC)诊断为SCF的患者57例,分为实验组(29例)和对照组(28例),对照组给予硝酸酯类药物、阿司匹林、曲美他嗪治疗;实验组在对照组治疗基础上加用阿托伐他汀20mg口服,疗程4周,观察两组临床症状、血脂、血清超敏C反应蛋白(hs-CRP)水平变化。结果:实验组患者临床症状缓解显效率优于对照组,差异有统计学意义(P<0.005);实验组血脂、hs-CRP水平下降,与对照组比较,差异有统计学意义(P<0.05)。结论:阿托伐他汀治疗SCF疗效明显,作用机制可能与抗炎有关。
出处 《实用医学杂志》 CAS 北大核心 2012年第19期3283-3285,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献9

  • 1Pekdemir H, Cin V G, Cicek D, et al. Slow coronary flow may be a sign of diffuse atherosclerosis. Contribution of FFR and IVUS [J]. Aeta Cardiol, 2004, 59(2):127-133.
  • 2Li J J, Qin X W, Li Z C, et al. lnereased plasma C-reactive protein and interleukin-6 concentrations in patients with slow coronary flow[J]. Clin Chim Acta, 2007, 385(122) :43-47.
  • 3Ridker P M, Stampfer M J, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease [J ]. JAMA, 2001, 285(19) :2481-2485.
  • 4Patel V B, Robbins M A, Topol E J. C-reactive protein: golden marker' for inilammation and coronary artery disease [J]. Cleve Clin J Med, 2001, 68(6) :521-524, 527-534.
  • 5Rifai N, Ridker P M. Highsensitivity C-reactive protein : novel and promising marker of coronary heart disease [J]. Clin Chem, 2001, 47 (3): 403-411.
  • 6Chapidze G, Dolidze N, Enquobahrie D A, et al. Metabolic syndrome and C-reactive protein among cardiology patients [J]. Arch Med Res, 2007, 38 (7):783-788.
  • 7Vongpatanasin W, Thomas G D, Schwartz R, et al. C-reactive protein causes downregulation of vascular angiotensin subtype receptors and systolic hypertension in mice [J]. Circulation, 2007, 115 ( 8 ) : 1020-1028.
  • 8Hein T W, Singh U, Vasquez-Vivar J, et al. Human C- reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo [J]. Atherosclerosis, 2009, 206(1 ) :61-68.
  • 9Devaraj S, Yun J M, Adamson G, et al. C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction [ J ]. Cardiovasc Res, 2009, 184(3) : 479-484.

同被引文献41

  • 1国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组报告《缺血性心脏病命名及诊断标准》[J].中华心血管病杂志,1981,9(1):75.
  • 2Neuvonen PJ. Drug interactions with HMG-CoA reductase in- hibitors(statins) :the importance of CY P enzymes, transport- ers and pharmacogenetic [ J ]. Current Opinion in Investigation- al Drugs ,2010,11 ( 3 ) :323-332.
  • 3Kinlay S,Ganz P. Endothelial dysfunction in coronary artery dis- ease and implications for therapy [J]. Am cardiol,1997,80(9A): 11-16.
  • 4Neuvonen PJ. Drug interactions with HMG-CoA reductase in- hibitors(statins):the importance of CY P enzymes,transporters and pharmacogenetic [J]. Current Opinion in Investigational Drugs, 2010,11(3) :323-332.
  • 5Jin YF,Han HC,Berger J,et al. Combining experimental and mathematical modeling to reveal mechanisms of macrophage-de- pendent left ventricular remodeling[J]. BMC Syst, 2011,5(1) : 60-7.
  • 6Choi' KY ,kim DB ,kim MJ ,et al. Higher plasma thrombospondin- 1 levels in patients with coronary artery disease mellitus[J]. Korean cire J ,2012:42(2) : 100-6.
  • 7Ghassibe-Sabbagh M,Platt DE,Youhanna S,et al. Genetic and environmental influences on total plasma homocysteine and its role in coronary artery disease risk [J]. Atherosclerosis,2012:222(1): 180-6.
  • 8Moroi M ,Zhang L,Yasuda T,et al. Interaction of genetic deficice- cy of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice[J].J Clin Invest, 1998,101 : 1225-1232.
  • 9Alexander Rw. Atherosclerosis as disease of redox-sensitive genes [J]. Trans Am Clin Climatol Assoc, 1998,109:129-145.
  • 10Feron O, Dessy C,Desager JP,et al. Hydroxy -methylglutaryl - coenzyme areductase inhabition promotes endothelial nitrc oxide synthase activation through a decrease in caveolin abundance [J]. Circulation, 2001,103(1) : 113-118.

引证文献6

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部